Global Influenza Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2025

Published: Nov, 2019 | Pages: 118 | Publisher: XYZResearch
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Influenza Drugs in these regions, from 2014 to 2026 (forecast), covering
    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia and Italy)
    South America (Brazil, Argentina, Columbia)
    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Influenza Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    Roche
    Shionogi
    Cipla
    Sun Pharmaceutical
    GlaxoSmithKline
    Mitsubishi Chemical
    Daiichi Sankyo
    ADMA Biologics
    Teva
    CSL
    Sanofi
    AstraZeneca
    Biondvax
    HEC
    China Resources Sanjiu
    BaiYunShan General Factory (BYS)
    Livzon Pharm
    Northeast Pharm
    Others
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Oseltamivir
    Zanamivir
    Amantadine
    Rimantadine
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Influenza Drugs for each application, including
    Hospital
    Pharmacy

If you have any special requirements, please let us know and we will offer you the report as you want.

 Table of Contents


Global Influenza Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
    1.1 Definition and Specification
    1.2 Report Overview
        1.2.1 Manufacturers Overview
        1.2.2 Regions Overview
        1.2.3 Type Overview
        1.2.4 Application Overview
    1.3 Industrial Chain
        1.3.1 Influenza Drugs Overall Industrial Chain
        1.3.2 Upstream
        1.3.3 Downstream
    1.4 Industry Situation
        1.4.1 Industrial Policy
        1.4.2 Product Preference
        1.4.3 Economic/Political Environment
    1.5 SWOT Analysis
2 Market Assessment by Type
   2.1 Oseltamivir Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
   2.2 Zanamivir Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
   2.3 Amantadine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
   2.4 Rimantadine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Influenza Drugs Market Assessment by Type
    3.1 Asia Pacific Market Performance (Sales, Revenue)
    3.2 Key Players in Asia Pacific
4 North America Influenza Drugs Market Assessment by Type
    4.1 North America Market Performance (Sales, Revenue)
    4.2 Key Players in North America
5 Europe Influenza Drugs Market Assessment by Type
    4.1 Europe Market Performance (Sales, Revenue)
    4.2 Key Players in Europe
6 South America Influenza Drugs Market Assessment by Type
    4.1 South America Market Performance (Sales, Revenue)
    4.2 Key Players in South America
7 Middle Easr and Africa Influenza Drugs Market Assessment by Type
    4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
    4.2 Key Players in Middle Easr and Africa
8 World Influenza Drugs Market Assessment by Type
    8.1 Asia Pacific Influenza Drugs Market Assessment by Application (Consumption and Market Share)
    8.2 North America Influenza Drugs Market Assessment by Application (Consumption and Market Share)
    8.3 Europe Influenza Drugs Market Assessment by Application (Consumption and Market Share)
    8.4 South America Influenza Drugs Market Assessment by Application (Consumption and Market Share)
    8.5 Middle East and Africa Influenza Drugs Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
    9.1 Roche
        9.1.1 Roche Profiles
        9.1.2 Roche Product Portfolio
        9.1.3 Roche Influenza Drugs Business Performance
        9.1.4 Roche Influenza Drugs Business Development and Market Status
    9.2 Shionogi
        9.2.1 Shionogi Profiles
        9.2.2 Shionogi Product Portfolio
        9.2.3 Shionogi Influenza Drugs Business Performance
        9.2.4 Shionogi Influenza Drugs Business Development and Market Status
    9.3 Cipla
        9.3.1 Cipla Profiles
        9.3.2 Cipla Product Portfolio
        9.3.3 Cipla Influenza Drugs Business Performance
        9.3.4 Cipla Influenza Drugs Business Development and Market Status
    9.4 Sun Pharmaceutical
        9.4.1 Sun Pharmaceutical Profiles
        9.4.2 Sun Pharmaceutical Product Portfolio
        9.4.3 Sun Pharmaceutical Influenza Drugs Business Performance
        9.4.4 Sun Pharmaceutical Influenza Drugs Business Development and Market Status
    9.5 GlaxoSmithKline
        9.5.1 GlaxoSmithKline Profiles
        9.5.2 GlaxoSmithKline Product Portfolio
        9.5.3 GlaxoSmithKline Influenza Drugs Business Performance
        9.5.4 GlaxoSmithKline Influenza Drugs Business Development and Market Status
    9.6 Mitsubishi Chemical
        9.6.1 Mitsubishi Chemical Profiles
        9.6.2 Mitsubishi Chemical Product Portfolio
        9.6.3 Mitsubishi Chemical Influenza Drugs Business Performance
        9.6.4 Mitsubishi Chemical Influenza Drugs Business Development and Market Status
    9.7 Daiichi Sankyo
        9.7.1 Daiichi Sankyo Profiles
        9.7.2 Daiichi Sankyo Product Portfolio
        9.7.3 Daiichi Sankyo Influenza Drugs Business Performance
        9.7.4 Daiichi Sankyo Influenza Drugs Business Development and Market Status
    9.8 ADMA Biologics
        9.8.1 ADMA Biologics Profiles
        9.8.2 ADMA Biologics Product Portfolio
        9.8.3 ADMA Biologics Influenza Drugs Business Performance
        9.8.4 ADMA Biologics Influenza Drugs Business Development and Market Status
    9.9 Teva
        9.9.1 Teva Profiles
        9.9.2 Teva Product Portfolio
        9.9.3 Teva Influenza Drugs Business Performance
        9.9.4 Teva Influenza Drugs Business Development and Market Status
    9.10 CSL
        9.10.1 CSL Profiles
        9.10.2 CSL Product Portfolio
        9.10.3 CSL Influenza Drugs Business Performance
        9.10.4 CSL Influenza Drugs Business Development and Market Status
    9.11 Sanofi
    9.12 AstraZeneca
    9.13 Biondvax
    9.14 HEC
    9.15 China Resources Sanjiu
    9.16 BaiYunShan General Factory (BYS)
    9.17 Livzon Pharm
    9.18 Northeast Pharm
    9.19 Others
10 World Influenza Drugs Market Assessment by Players
    10.1 Global Influenza Drugs Sales (K Units) and Market Share by Players 2014-2020
    10.2 Global Influenza Drugs Revenue (M USD) and Market Share by Players 2014-2020
    10.3 Global Influenza Drugs Price (USD/Unit) of Players 2014-2020
    10.4 Global Influenza Drugs Gross Margin of Players 2014-2020
    10.5 Market Concentration
11 Regional Market Performance by Segment of Players
    11.1 North America
        11.1.1 North America Influenza Drugs Sales Assessment of Players 2014-2020
        11.1.2 North America Influenza Drugs Revenue Assessment of Players 2014-2020
        11.1.3 North America Influenza Drugs Price Assessment of Players 2014-2020
        11.1.4 North America Influenza Drugs Gross Margin Assessment of Players 2014-2020
        11.1.5 Market Concentration
    11.2 Europe
        11.2.1 Europe Influenza Drugs Sales Assessment of Players 2014-2020
        11.2.2 Europe Influenza Drugs Revenue Assessment of Players of Manufacturers 2014-2020
        11.2.3 Europe Influenza Drugs Price Assessment of Players 2014-2020
        11.2.4 Europe Influenza Drugs Gross Margin Assessment of Players 2014-2020
        11.2.5 Market Concentration
    11.3 Asia-Pacific Market Performance for Manufacturers
        11.3.1 Asia-Pacific Influenza Drugs Sales Assessment of Players 2014-2020
        11.3.2 Asia-Pacific Influenza Drugs Revenue Assessment of Players 2014-2020
        11.3.3 Asia-Pacific Influenza Drugs Price Assessment of Players 2014-2020
        11.3.4 Asia-Pacific Influenza Drugs Gross Margin Assessment of Players 2014-2020
        11.3.5 Market Concentration
    11.4 South America Market Performance for Players
        11.4.1 South America Influenza Drugs Sales Assessment of Players 2014-2020
        11.4.2 South America Influenza Drugs Revenue Assessment of Players 2014-2020
        11.4.3 South America Influenza Drugs Price Assessment of Players 2014-2020
        11.4.4 South America Influenza Drugs Gross Margin Assessment of Players 2014-2020
        11.4.5 Market Concentration
    11.5 Middle East and Africa  Market Performance for Players
        11.5.1 Middle East and Africa  Influenza Drugs Sales Assessment of Players 2014-2020
        11.5.2 Middle East and Africa  Influenza Drugs Revenue Assessment of Players 2014-2020
        11.5.3 Middle East and Africa  Influenza Drugs Price Assessment of Players 2014-2020
        11.5.4 Middle East and Africa  Influenza Drugs Gross Margin Assessment of Players 2014-2020
        11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
    12.1 Asia Pacific
        12.1.1 Asia Pacific Influenza Drugs Sales by Countries/Regions 2014-2020
        12.1.2 Asia Pacific Influenza Drugs Revenue by Countries/Regions 2014-2020
        12.1.3 Asia Pacific Influenza Drugs Average Price by Countries/Regions 2014-2020
    12.2 North America
        12.2.1 North America Influenza Drugs Sales by Countries/Regions 2014-2020
        12.2.2 North America Influenza Drugs Revenue by Countries/Regions 2014-2020
        12.2.3 North America Influenza Drugs Average Price by Countries/Regions 2014-2020
    12.3 Europe
        12.3.1 Europe Influenza Drugs Sales by Countries/Regions 2014-2020
        12.3.2 Europe Influenza Drugs Revenue by Countries/Regions 2014-2020
        12.3.3 Europe Influenza Drugs Average Price by Countries/Regions 2014-2020
    12.4 South America
        12.4.1 South America Influenza Drugs Sales by Countries/Regions 2014-2020
        12.4.2 South America Influenza Drugs Revenue by Countries/Regions 2014-2020
        12.4.3 South America Influenza Drugs Average Price by Countries/Regions 2014-2020
    12.5 Middle East and Africa
        12.5.1 Middle East and Africa Influenza Drugs Sales by Countries/Regions 2014-2020
        12.5.2 Middle East and Africa Influenza Drugs Revenue by Countries/Regions 2014-2020
        12.5.3 Middle East and Africa Influenza Drugs Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
     13.1 Technology
     13.2 Market Opportunity
14 World Influenza Drugs Sales & Revenue Forecast 2021-2026
     14.1 World Influenza Drugs Sales and Revenue Forecast by Regions 2021-2026
        14.1.1 World Influenza DrugsSales and Market Share by Regions
        14.1.2 World Influenza DrugsRevenue and Market Share by Regions
15 Asia Influenza Drugs Market Forecast 2021-2026
     15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
        15.1.1 Oseltamivir
        15.1.2 Zanamivir
        15.1.3 Amantadine
        15.1.4 Rimantadine
     15.2 Consumption Forecast by Application, 2021-2026
16 North America Influenza Drugs Market Forecast 2021-2026
     16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
        16.1.1 Oseltamivir
        16.1.2 Zanamivir
        16.1.3 Amantadine
        16.1.4 Rimantadine
     16.2 Consumption Forecast by Application, 2021-2026
17 Europe Influenza Drugs Market Forecast 2021-2026
     17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
        17.1.1 Oseltamivir
        17.1.2 Zanamivir
        17.1.3 Amantadine
        17.1.4 Rimantadine
     17.2 Consumption Forecast by Application, 2021-2026
18 South America Influenza Drugs Market Forecast 2021-2026
     18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
        18.1.1 Oseltamivir
        18.1.2 Zanamivir
        18.1.3 Amantadine
        18.1.4 Rimantadine
     18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Influenza Drugs Market Forecast 2021-2026
     19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
        19.1.1 Oseltamivir
        19.1.2 Zanamivir
        19.1.3 Amantadine
        19.1.4 Rimantadine
     19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
     20.1 Global Influenza Drugs Price (USD/Unit) Trend 2021-2026
     20.2 Global Influenza Drugs Gross Profit Trend 2021-2026
21 Conclusion